The Miracle

Chemothera­py causes Cancer?

- By Scott Stockdale

Despite the continued use of chemothera­py as the mainstay to treat cancer patients, researcher­s recently increased their estimate of the number of Canadians who will die from cancer from two-in-five, to one-in-two. Meanwhile, a 14-year study published in the Journal of Clinical Oncology in December 2004 called “The Contributi­on of Cytotoxic Chemothera­py to 5-year Survival in Adult Malignanci­es” (Clinical Oncology (2004) 16: 549e560 doi: 10.1016/ j. clon. 2004.06.007) showed that the overall contributi­on of curative and adjuvant cytotoxic chemothera­py to 5-year survival in adults was estimated to be 2.3 in Australia and 2.1 in the United States. Moreover, several doctors have stated on the record that chemothera­py actually causes more cancer to develop in patients. According to Dr. John Diamond, M.D., “A study of over 10,000 patients shows clearly that chemo’s supposedly strong track record with Hodgkin’s disease (lymphoma) is actually a lie. Patients who underwent chemo were 14 times more likely to develop leukemia and 6 times more likely to develop cancers of the bones, joints, and soft tissues than those patients who did not undergo chemothera­py.” Moreover, Dr. Allen Levin and Dr. Glen Warner said chemothera­py actually kills the patients before the cancer does. The late Dr. Glenn Warner (he died in 2000) – one of the most highly qualified cancer specialist­s in American - used alternativ­e treatments on his cancer patients with great success. He said chemothera­py was killing people for profit. “We have a multi-billion dollar industry that is killing people, right and left, just for financial gain. Their idea of research is to see whether two doses of this poison is better than three doses of that poison.” Dr. Allen Levin concurred with Dr. Warner’s conclusion that chemothera­py kills people. “Most cancer patients in this country die of chemothera­py. Chemothera­py does not eliminate breast, colon, or lung cancers. This fact has been documented for over a decade, yet doctors still use chemothera­py for these tumors,” Dr. Levin said. In his book, The Topic of Cancer: When the Killing Has to Stop, Dick Richards cites a number of autopsy studies which have shown that cancer patients actually died from convention­al treatments before the tumor had a chance to kill them. Dr. Petter Glidden, a member of the American Associatio­n of Naturopath­ic Physicians and the Illinois Associatio­n of Naturopath­ic Physicians, who received his BS degree from the University of Massachuse­tts in Amhurst and earned his ND from Bastyr University in Seattle, Washington, said chemothera­py is still used because doctors and pharmaceut­ical companies make money from it. “That’s the only reason: not because it’s effective, decreases morbidity, mortality or diminishes any specific cancer rates. In fact, it does the opposite. Chemothera­py boosts cancer growth and long-term mortality rates. Most chemothera­py patients either die or are plagued with illness within 10-15 years after treatment. It destroys their immune system, increases neuro-cognitive decline, disrupts endocrine functionin­g and causes organ and metabolic toxicities. Patients basically live in a permanent state of disease until their death.” Moreover, he added that “The cancer industry” (pharmaceut­ical companies and doctors) marginaliz­es safe and effective cures while promoting their patented, expensive, and toxic remedies, whose risks far exceed any benefit. “This is what they do best, and they do it because it makes money, plain and simple.” Dr. Glidden said toxic chemothera­py drugs just happen to take a little longer to kill than many other poisonous substances – such as cyanide and arsenic - and he said they’re designed that way for a good reason. “We couldn’t have people dropping like flies one week after receiving chemo or the gig would be over. Again, that would be bad for business.” With these kind of claims, one has to wonder how researcher­s manage to promulgate a “one-intwo” chance of survival for those who take convention­al cancer treatments, which means chemothera­py and radiation. Dr. Glidden said it’s clear to any trained eye that initial lesions that are doubtful, or debatable, as to whether or not they are malignant, represent the overwhelmi­ng majority of the tumours being detected. In other words, patients with these lesions are either unlikely, or much less likely to develop malignant cancer than those who definitely cancer tumours. By including these initial lesions, which Dr. Glidden characteri­zes as “presumed neoplasias”, researcher­s are able to inflate survival rates for chemothera­py patients. “It is equally clear how often these presumed neoplasias (tumours), which are often subject to both misunderst­anding and manipulati­on, inflate those statistics to the point of implausibi­lity.” He added that the reason a five-year relative survival rate is the standard used to assess mortality rates is due to most cancer patients going downhill after this period. Meanwhile, Dr. Glidden said if the long-term statistics (ten plus years) for all cancers administer­ed chemothera­py produced the objective data on rigorous evaluation­s, including the cost-effectiven­ess, impact on the immune system, quality of life, morbidity and mortality, it would be very clear that chemothera­py makes little to no contributi­on to cancer survival at all. But he intimated that this is not going to happen any time soon because researcher­s are funded by corporatio­ns - mainly pharmaceut­ical companies - which make a fortune from chemothera­py drugs. “No such study has ever been conducted by independen­t investigat­ors in the history of chemothera­py. The only studies available come from (cancer) industry funded institutio­ns and scientists and none of them have ever inclusivel­y quantified the above variables.” He added that clinical studies never inclusivel­y assess the long-term survival and recovery rates of cancer patients because damage to the immune system, organ and metabolic toxicities, endocrine challenges and neurocogni­tive problems slowly develops after chemothera­py. “It often does not begin to manifest throughout the body until several months or even years have passed. It takes time, but within a 3-5 year period, most chemothera­py patients begin to have many more symptoms of disease than they ever had before their diagnosis, due to and as a direct result of cytotoxic drug interventi­on.” This may be, in no small part, because chemothera­py does not target cancer cells and it kills far more normal cells than cancer cells and damages and toxifies many of the normal cells that do survive.

 ??  ??

Newspapers in English

Newspapers from Canada